May 5, 2026
Investment Reports Interviews Thomas Madden – CEO, Acuitas Therapeutics
What differentiates us is our full “soup to nuts” capability—we support process development, scale-up, and provide clinical and regulatory expertise. This ability to de-risk partner programs is highly attractive.
“Vancouver is the global epicentre for LNP research, so we can recruit locally with strong expertise.”